Human Pathology
Volume 41, Issue 6 , Pages 848-858 , June 2010

Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells

  • Hussein Fakhry, MD

      Affiliations

    • Surgical Oncology Department, South Egypt Cancer Institute Assiut University, Assiut 7111, Egypt
    • ,
  • Tsutomu Miyamoto, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
    • ,
  • Hiroyasu Kashima, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
    • ,
  • Akihisa Suzuki, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
    • ,
  • He Ke, MD

      Affiliations

    • Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
    • ,
  • Ikuo Konishi, MD, PhD

      Affiliations

    • Department of Gynecology and Obstetrics, Kyoto University Faculty of Medicine, Kyoto 606-8527, Japan
    • ,
  • Tanri Shiozawa, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.

Received 30 May 2009 ,Revised 18 November 2009 ,Accepted 20 November 2009.

References 

  1. Ronnett B, Zaino R, Ellenson L, Kurman R. In: Endometrial carcinoma. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer-Verlag; 2002;p. 501–559
  2. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2008;111:436–447
  3. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105–S143
  4. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198:218.e1–218.e6
  5. Li SF, Shiozawa T, Nakayama K, Nikaido T, Fujii S. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer. 1996;77:321–329
  6. Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol. 2003;34:471–478
  7. Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98:604–610
  8. Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncology. 2008;9:139–148
  9. Krusche CA, Vloet AJ, Classen-Linke I, et al. Histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod. 2007;22:2956–2966
  10. Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8:381
  11. Felsenfeld G. Chromatin as an essential part of the transcriptional mechanism. Nature. 1992;355:219–224
  12. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41–45
  13. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000;97:10014–10019
  14. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999;9:40–48
  15. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38–51
  16. Weichert W, Denkert C, Noske A, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008;10:1021–1027
  17. Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–1149
  18. Jiang S, Dowdy SC, Meng XW, et al. Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecol Oncol. 2007;105:493–500
  19. Ahn MY, Lee J, Na YJ, et al. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact. 2009;179:169–177
  20. Ueda T, Takai N, Nishida M, Nasu K, Narahara H. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med. 2007;19:301–308
  21. Shiozawa T, Miyamoto T, Kashima H, Nakayama K, Nikaido T, Konishi I. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene. 2004;23:8603–8610
  22. Nagy L, Kao HY, Chakravarti D, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 1997;89:373–380
  23. Shiozawa T, Shih HC, Miyamoto T, et al. Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. J Clin Endocrinol Metab. 2003;88:871–878
  24. Sakai N, Maruyama T, Sakurai R, et al. Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells. J Biol Chem. 2003;278:16675–16682
  25. Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology. 2005;146:5365–5373
  26. Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14:1669–1677
  27. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene. 1998;16:2549–2556
  28. Inokoshi J, Katagiri M, Arima S, et al. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem Biophys Res Commun. 1999;256:372–376
  29. Margueron R, Licznar A, Lazennec G, Vignon F, Cavailles V. Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol. 2003;179:41–53
  30. Han JW, Ahn SH, Park SH, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 2000;60:6068–6074
  31. Cheong JW, Chong SY, Kim JY, et al. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl–positive leukemia cells. Clin Cancer Res. 2003;9:5018–5027
  32. Jones P, Altamura S, De Francesco R, et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J Med Chem. 2008;51:2350–2353
  33. Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007;117:659–671
  34. Roh MS, Kim CW, Park BS, et al. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis. 2004;9:583–589
  35. Woo HJ, Lee SJ, Choi BT, Park YM, Choi YH. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol. 2007;82:77–84
  36. Alao JP, Stavropoulou AV, Lam EW, Coombes RC. Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer. 2006;5:40

PII: S0046-8177(09)00430-4

doi: 10.1016/j.humpath.2009.11.012

Human Pathology
Volume 41, Issue 6 , Pages 848-858 , June 2010

Article Tools

* Image Usage & Resolution